Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Trial Profile

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2012

At a glance

  • Drugs Zanolimumab (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Emergent BioSolutions
  • Most Recent Events

    • 14 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top